The Power of Fully Connected Continuous Manufacturing: Driving Down mAb Costs to US$40 per Gram

This presentation features: Shilpa Gadgil, PhD, VP, Head of Process and Analytical Development, Head of CDMO Development, Enzene.

Expensive manufacturing processes continue to impede patient access to therapies based on monoclonal antibodies (mAbs). Enzene’s Shilpa Gadgil pointed out that mAbs produced in conventional fed-batch processes cost US$180–500 per gram, bringing treatment prices to about $10,000 annually. But in India, where the average annual income is below $18,000, many patients cannot afford such treatments. New manufacturing technologies will be critical to increasing mAb access.

Register or Login and hit Download Now to watch the full presentation now.

The summary of this presentation was published in the BPI Theater at BIO 2025 Day One: Global Supply Chain, Capacity, Access, and Affordability of Biopharmaceuticals eBook.

Source : https://www.bioprocessintl.com/